Hepatic Angiography: A Procedure to Visualize Liver Tumor Vessels in a Rabbit Model

Executive Industry Relevance

Visualizing tumor-associated vasculature enables mechanistic de-risking in oncology target validation by clarifying angiogenic pathways and perfusion dynamics. This preclinical imaging approach supports predictive confidence in therapeutic hypotheses and informs go/no-go decisions for vascular-targeted agents. The rabbit VX2 liver model provides a disease-relevant system for evaluating drug delivery and tumor response in early discovery.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Interrogates therapeutic hypotheses by visualizing tumor vasculature and angiogenic signaling.
• Operational Value: Enables functional target validation through real-time perfusion assessment.
• Predictive Value: Supports portfolio triage by clarifying mechanistic pathways and reducing biological ambiguity.

Screening & Assay Development

• Scientific Value: Prepares validated biological systems for downstream compound screening by establishing vascular baseline.
• Operational Value: Standardizes imaging readouts for reproducible quantitative analysis of vascular responses.
• Platform Value: Enhances assay scalability and reuse in preclinical angiogenesis and vascular normalization studies.

Translational & Preclinical Research

• Scientific Value: Aligns with translational biomarker strategies by linking vascular imaging to tumor phenotype.
• Operational Value: Ensures continuity from discovery through preclinical validation via consistent hemodynamic monitoring.
• Risk Mitigation: Informs risk-adjusted advancement decisions by visualizing therapeutic access and delivery efficiency.

Pipeline & Workflow Integration

This method integrates into the discovery continuum from target validation through lead identification to preclinical evaluation by providing vascular imaging readouts that inform mechanistic understanding and therapeutic indexing.

• Discovery Biology: Supports hypothesis testing and pathway clarification by visualizing tumor-associated blood flow and angiogenic markers.
• Screening: Enables assay readiness through standardized vascular visualization and quantitative contrast dynamics.
• Analytics: Delivers quantitative measurements of perfusion, vessel density, and contrast retention for comparative condition analysis.
• Translational Research: Connects to preclinical continuity by aligning vascular imaging with biomarker expression and therapeutic response.
• Enterprise Reuse: Functions as a reusable imaging platform across oncology projects requiring vascular phenotype assessment.

Operational & Enterprise Impact

• Scientific Value: Predictive confidence, target validation, reduction of mechanistic ambiguity in angiogenic pathways.
• Operational Value: Standardization, reproducibility, and scalability of vascular imaging across study cohorts.
• Strategic Value: Better go/no-go decisions, capital efficiency, and reduced late-stage biological risk in vascular-targeted programs.
• Portfolio Impact: Risk-adjusted prioritization and advancement decisions based on vascular accessibility and drug delivery metrics.

Implementation Considerations

• Requires expertise in vascular access, catheterization, and fluoroscopic imaging.
• Dependent on angiography-compatible instrumentation and contrast agent infrastructure.
• Necessitates cross-team standardization between interventional radiology and oncology teams.
• Adaptation considerations include model-specific vascular anatomy and tumor hypervascularity thresholds.
• Practical limitations include procedural complexity and contrast-induced artifacts in fibrotic or necrotic tumors.

Biopharma FAQs